Bottom line
On 30 July 2026, aficamten received UK marketing authorisation and a positive NICE recommendation for adults with symptomatic obstructive hypertrophic cardiomyopathy. The coordinated timing is notable, but the recommendation still applies to a defined population and treatment pathway.
What aficamten is designed to do
Aficamten is an oral cardiac myosin inhibitor intended to reduce the excessive contractility that contributes to left-ventricular outflow obstruction. The aim is to improve functional capacity and symptoms in obstructive HCM, not to treat every form of HCM.
What the phase 3 evidence adds
SEQUOIA-HCM randomized 282 adults with symptomatic obstructive HCM to aficamten or placebo for 24 weeks. The trial reported improvement in peak oxygen uptake and other symptom and obstruction measures with aficamten. Duration, monitoring and the selected trial population matter when applying those findings.
Why the UK decision needs two lenses
The MHRA decision addresses quality, safety and efficacy for the licensed indication. NICE used a cost-comparison route against mavacamten and recommended aficamten for NHS use in the specified population. The government announcement estimated that around 6,600 people in England could benefit.
What this brief does not establish
- It does not identify which individual patient should receive aficamten.
- It does not replace contraindications, interaction checks, cardiac imaging or product-information monitoring.
- It does not imply benefit in non-obstructive or asymptomatic HCM.
- Local pathways and specialist assessment still determine actual access and treatment decisions.
Evidence snapshot
- Population
- 282 adults with symptomatic obstructive HCM in SEQUOIA-HCM
- Design
- International phase 3, randomized, double-blind, placebo-controlled
- Follow-up
- 24-week treatment period for the pivotal comparison
- Primary outcome
- Change in peak oxygen uptake on cardiopulmonary exercise testing
- UK status
- MHRA authorised and NICE recommended on 30 July 2026
- Important boundary
- Specialist selection and monitoring remain essential
Evidence, interpreted
Quick analysis
- Study design
- International phase 3, randomised, double-blind, placebo-controlled trial; peer-reviewed publication.
- Population
- 282 adults with symptomatic obstructive hypertrophic cardiomyopathy treated for 24 weeks.
- Principal finding
- Aficamten improved peak oxygen uptake and several symptom and obstruction measures compared with placebo over 24 weeks.
- Limitations
- The pivotal comparison lasted 24 weeks, so it was not designed to establish long-term clinical-event or survival benefit.
- Participants were selected for a specialist trial and the result does not extend automatically to non-obstructive or asymptomatic HCM.
- Ongoing imaging, dose selection and specialist monitoring remain part of translating efficacy into routine care.
- Residual uncertainty
- Long-term outcomes, comparative effectiveness across myosin inhibitors and delivery through routine specialist pathways need continued evaluation.
- Conflicts or funding
- SEQUOIA-HCM was funded by Cytokinetics, the medicine’s developer; the paper’s author disclosures remain relevant to interpretation.
- UK-practice impact
- ChangedThe MHRA authorised aficamten and NICE recommended it for a defined NHS population; this does not make it appropriate for every person with HCM.
Original sources
- TA1181: Aficamten for symptomatic obstructive HCMNICE ↗
- Co-ordinated MHRA and NICE decisionsMedicines and Healthcare products Regulatory Agency ↗
- Aficamten for Symptomatic Obstructive Hypertrophic CardiomyopathyNew England Journal of Medicine ↗
- NCT05186818 trial recordClinicalTrials.gov ↗
Sources last checked 10 August 2026. If an official source and this summary differ, use the official source.